FR20C1044I2 - Triazines pour le traitement des infections protozoïques - Google Patents

Triazines pour le traitement des infections protozoïques

Info

Publication number
FR20C1044I2
FR20C1044I2 FR20C1044C FR20C1044C FR20C1044I2 FR 20C1044 I2 FR20C1044 I2 FR 20C1044I2 FR 20C1044 C FR20C1044 C FR 20C1044C FR 20C1044 C FR20C1044 C FR 20C1044C FR 20C1044 I2 FR20C1044 I2 FR 20C1044I2
Authority
FR
France
Prior art keywords
triazines
treatment
protozoic
infections
protozoic infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1044C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceva Sante Animale SA
Original Assignee
Ceva Sante Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47351540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1044(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ceva Sante Animale SA filed Critical Ceva Sante Animale SA
Publication of FR20C1044I1 publication Critical patent/FR20C1044I1/fr
Application granted granted Critical
Publication of FR20C1044I2 publication Critical patent/FR20C1044I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
FR20C1044C 2012-12-07 2020-09-16 Triazines pour le traitement des infections protozoïques Active FR20C1044I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306546.8A EP2740469A1 (fr) 2012-12-07 2012-12-07 Nouveaux traitements avec des triazines
PCT/EP2013/075755 WO2014086958A1 (fr) 2012-12-07 2013-12-06 Nouveaux traitements par des triazines
EP13802596.0A EP2928454B1 (fr) 2012-12-07 2013-12-06 Triazines pour le traitement des infections protozoïques

Publications (2)

Publication Number Publication Date
FR20C1044I1 FR20C1044I1 (fr) 2020-10-30
FR20C1044I2 true FR20C1044I2 (fr) 2021-10-15

Family

ID=47351540

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1044C Active FR20C1044I2 (fr) 2012-12-07 2020-09-16 Triazines pour le traitement des infections protozoïques

Country Status (23)

Country Link
US (1) US9877969B2 (fr)
EP (3) EP2740469A1 (fr)
JP (1) JP6125034B2 (fr)
KR (1) KR102253497B1 (fr)
CN (3) CN104981233A (fr)
AU (1) AU2013353982B2 (fr)
BR (3) BR122021005311B1 (fr)
CA (1) CA2892886C (fr)
CL (1) CL2015001563A1 (fr)
CY (1) CY1123190T1 (fr)
DK (1) DK2928454T3 (fr)
ES (1) ES2778950T3 (fr)
FR (1) FR20C1044I2 (fr)
HR (1) HRP20200630T1 (fr)
HU (2) HUE049950T2 (fr)
MX (1) MX387072B (fr)
NL (1) NL301064I2 (fr)
PH (1) PH12015501220A1 (fr)
PL (1) PL2928454T3 (fr)
PT (1) PT2928454T (fr)
RU (1) RU2696265C2 (fr)
SI (1) SI2928454T1 (fr)
WO (1) WO2014086958A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
EP2740469A1 (fr) 2012-12-07 2014-06-11 Ceva Sante Animale Nouveaux traitements avec des triazines
EP2740492A1 (fr) 2012-12-07 2014-06-11 Ceva Sante Animale Formulations de triazines avec un principe actif additionnel et tensioactif(s)
EP2740470A1 (fr) * 2012-12-07 2014-06-11 Ceva Sante Animale Traitement de la coccidiose avec des compositions de triazine intramusculaire
EP3578182A1 (fr) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations contenant des triazinones et du fer ayant une faible quantité d'ions de fer libres
EP3578181A1 (fr) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation destinée au traitement simultané d'infections coccidiennes et de déficiences en fer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
US4493826A (en) * 1982-01-25 1985-01-15 Schering Corporation Gentamicin-gleptoferron compositions
DE3300793A1 (de) 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
US5219853A (en) 1983-01-12 1993-06-15 Bayer Aktiengesellschaft Agent for coccidiosis
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
JPH0776524A (ja) * 1993-07-13 1995-03-20 Takeda Chem Ind Ltd 動物用抗貧血剤
DE19603984A1 (de) 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
DE19603954C2 (de) 1996-02-05 2003-04-17 Wagon Automotive Gmbh Prallträger für ein Kraftfahrzeug
DE19824483A1 (de) 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
MXPA01003542A (es) 1998-10-08 2002-09-18 New Ace Res Company Composiciones y metodos nuevos para la prevencion y tratamiento de enfermedad causada por protozoarios.
AU4034800A (en) 1999-10-08 2001-04-23 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
KR101225216B1 (ko) 2004-12-01 2013-01-22 아큐샷 인크. 무침 주사기
PL2023981T3 (pl) 2006-06-07 2020-10-19 Acushot Inc. Mechanizm ładowania dla wstrzykiwacza bezigłowego
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
DE102007025908A1 (de) * 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
US20110288521A1 (en) 2008-03-07 2011-11-24 Pharma Jet ,Inc. Intradermal injector and uses thereof
SI22751A (sl) 2008-04-03 2009-10-31 Krka, D.D., Novo Mesto Toltrazuril z izboljĺ animi lastnostmi za raztapljanje
FR2946882B1 (fr) 2009-06-18 2011-08-26 Ceva Sante Animale Suspension veterinaire gelifiee de fer
CN101947201B (zh) 2010-09-08 2011-12-28 洛阳惠中兽药有限公司 兽药纳米混悬剂及其制备方法与应用
CN102512366A (zh) 2011-12-28 2012-06-27 广州市和生堂动物药业有限公司 妥曲珠利悬浮乳剂及其制备方法
CN102743334A (zh) 2012-07-30 2012-10-24 郑州后羿制药有限公司 一种妥曲珠利注射剂及其制备方法
EP2740492A1 (fr) 2012-12-07 2014-06-11 Ceva Sante Animale Formulations de triazines avec un principe actif additionnel et tensioactif(s)
EP2740470A1 (fr) * 2012-12-07 2014-06-11 Ceva Sante Animale Traitement de la coccidiose avec des compositions de triazine intramusculaire
EP2740469A1 (fr) 2012-12-07 2014-06-11 Ceva Sante Animale Nouveaux traitements avec des triazines
EP3578181A1 (fr) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation destinée au traitement simultané d'infections coccidiennes et de déficiences en fer

Also Published As

Publication number Publication date
CN112370454A (zh) 2021-02-19
HUE049950T2 (hu) 2020-11-30
HRP20200630T1 (hr) 2020-07-10
US9877969B2 (en) 2018-01-30
HUS2000037I1 (hu) 2020-10-28
BR122021005310B1 (pt) 2022-01-25
PL2928454T3 (pl) 2020-08-24
EP2740469A1 (fr) 2014-06-11
ES2778950T3 (es) 2020-08-12
CN104981233A (zh) 2015-10-14
RU2015127025A (ru) 2017-01-12
JP6125034B2 (ja) 2017-05-10
JP2016501252A (ja) 2016-01-18
BR112015013182A2 (pt) 2017-07-11
PH12015501220B1 (en) 2015-08-17
RU2696265C2 (ru) 2019-08-01
CA2892886C (fr) 2021-09-07
BR122021005311B1 (pt) 2022-01-25
WO2014086958A1 (fr) 2014-06-12
AU2013353982B2 (en) 2018-01-04
MX2015007128A (es) 2015-10-14
CY1123190T1 (el) 2021-10-29
EP2928454A1 (fr) 2015-10-14
US20150313905A1 (en) 2015-11-05
EP3721869A1 (fr) 2020-10-14
EP2928454B1 (fr) 2020-03-18
PH12015501220A1 (en) 2015-08-17
CL2015001563A1 (es) 2015-10-23
FR20C1044I1 (fr) 2020-10-30
NL301064I2 (nl) 2021-03-03
SI2928454T1 (sl) 2020-07-31
AU2013353982A1 (en) 2015-06-11
PT2928454T (pt) 2020-04-23
CA2892886A1 (fr) 2014-06-12
DK2928454T3 (da) 2020-03-30
KR20150104565A (ko) 2015-09-15
MX387072B (es) 2025-03-19
CN113144202A (zh) 2021-07-23
KR102253497B1 (ko) 2021-05-21

Similar Documents

Publication Publication Date Title
ZA201501018B (en) Compounds for the treatment of paramoxyvirus viral infections
PL2852391T3 (pl) Układy do leczenia infekcji płuc
EP3011515A4 (fr) Traitement de transactions vocales
EP2968208A4 (fr) Traitement de la cataplexie
SI3409667T1 (sl) Amidne spojine za zdravljenje okužb s HIV
FR20C1044I2 (fr) Triazines pour le traitement des infections protozoïques
SI2943493T1 (sl) Terapevtske spojine za zdravljenje virusnih infekcij
EP2875824A4 (fr) Composition pour la prévention ou le traitement de la cachexie
EP2914274A4 (fr) Probiotique modifié génétiquement pour le traitement de la phénylcétonurie
EP2882444A4 (fr) Silicate de zirconium microporeux pour le traitement de l'hyperkaliémie
PL2839230T3 (pl) Instalacja do obróbki obiektów
EP2919788A4 (fr) Méthodes et compositions pour le traitement de la schizophrénie
EP2807111A4 (fr) Nanomatériaux multifonctionnels pour le traitement du cancer
EP2887931A4 (fr) Composition pour le traitement des maux de tête de type migraine
EP2852571A4 (fr) Compositions et méthodes pour le traitement de la mucosite
EP2897613A4 (fr) Compositions de traitement
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
EP2773774A4 (fr) Biomarqueurs pour le traitement de tslp
FR3010188B1 (fr) Procede theragnostique pour le traitement des rhumatismes inflammatoires chroniques
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
HRP20181799T1 (hr) Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka
EP2968478A4 (fr) Compositions et procédés pour le traitement de la carboxyhémoglobinémie
EP2536436A4 (fr) Antimir-451 pour le traitement de polycythémies
EP2886122A4 (fr) Agent pour le traitement du cancer
FR3015285B1 (fr) Formulation pour le traitement des cheveux